Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Endocrine System Diseases: early-phase trial registry
4 of 12 indexed Endocrine System Diseases trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #1,429 of 28,707 conditions by registered trial count.
12 US clinical trials · 4 currently recruiting · #1,429 of 28,707 conditions by registered trial count
Endocrine System Diseases: 12 US clinical trials tracked, 4 recruiting.
Endocrine System Diseases is the subject of 12 registered US clinical trials on ClinicalTrials.gov, 4 of them currently open to new participants. 3 are in Phase 3-4 (later-stage) and 5 in Phase 1-2 (earlier-stage). The most active sponsor is Sling Therapeutics, running 2 of these trials.
Enrollment posture brief
Registry condition endocrine-system-diseases
OPEN 4 | RECR 33% | LATE 3 | EARLY 5 | RANK #1429 | SPON 2
Volume-matched condition peers
Nearest open-share peer: Adherence, Treatment (33% recruiting · 6 trials)
Endocrine System Diseases lists 4 open slots (33% of 12 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Endocrine System Diseases on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Endocrine System Diseases is recruiting below its size-band peers.
4 of 12 indexed trials (33.3%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Endocrine System Diseases research.
Sling Therapeutics accounts for 2 of 12 trials (16.7%). 11 distinct sponsors appear on at least one study for this condition label.
-
Typical Endocrine System Diseases enrolment sits around 90 participants.
Median target enrolment is 90 among the 12 trials that report a genuine target (sentinel values excluded). 7 of those (58.3%) plan for fewer than 100 participants.
-
Endocrine System Diseases research is mostly interventional.
10 interventional and 2 observational studies make up this index (83.3% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
12 total, page 1 of 1
Rare and Atypical Diabetes Network
University of South Florida
NCT05544266
Extension Study of Two Doses of Linsitinib in Subjects With Active, Moderate to Severe Thyroid Eye Disease (TED)
Sling Therapeutics
NCT06112340
In-Person Lifestyle Program for Black Adolescent Girls at Risk for Type 2 Diabetes
Cornell University
NCT06557317
Locomotor Training With Testosterone to Promote Bone and Muscle Health After Spinal Cord Injury
North Florida Foundation for Research and Education
NCT04460872
Evaluation of the Safety and Efficacy of Eneboparatide (AZP-3601) in Patients With Chronic Hypoparathyroidism
Alexion Pharmaceuticals
NCT05778071
A Phase 2b, Study of Linsitinib in Subjects With Active, Moderate to Severe Thyroid Eye Disease (TED)
Sling Therapeutics
NCT05276063
Intestinal Metabolic Reprogramming as a Key Mechanism of Gastric Bypass in Humans
University of Pittsburgh
NCT02710370
Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study)
Celgene
NCT01964430
A Trial to Compare the Efficacy and Safety of Once-weekly Lonapegsomatropin With Placebo and a Daily Somatropin Product in Adults With Growth Hormone Deficiency
Ascendis Pharma Endocrinology Division A/S
NCT04615273
Day and Night Closed-loop in Young People With Type 1 Diabetes
Jaeb Center for Health Research
NCT02925299
Single-Dose And Multiple-Dose Safety And Tolerability Study Of PF-04856883 In Type 2 Diabetic Adult Females
Pfizer
NCT01301456
First-In-Human Study of GFB-024 in Healthy Overweight and Obese Participants, and Participants With Type 2 Diabetes
Goldfinch Bio
NCT04880291
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 2 |
| Phase 2 | 3 |
| Phase 3 | 3 |
Top Sponsors
Named interventions
Most-linked intervention names on Endocrine System Diseases records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Endocrine System Diseases trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Endocrine System Diseases page
12 registered trials, 4 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 4 Endocrine System Diseases trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Sling Therapeutics sponsors the most Endocrine System Diseases trials on record, review their full trial history before evaluating a specific study. See Sling Therapeutics's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Endocrine System Diseases condition card totals 12 registered trials; most-linked intervention Placebo; top US site state Florida. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.